The company now expects $650 million to $700 million in revenue for the year, down from previous guidance of $700 million to ...

NVAX reports encouraging third-quarter results. However, the stock falls due to management lowering its sales guidance, ...

Novavax, Inc. (NASDAQ:NVAX) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning and welcome to Novavax' ...

BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. Eric Joseph has given his Sell rating due to a combination of ...

The US Food and Drug Administration (FDA) has removed the clinical hold on the Investigational New Drug (IND) application for ...

Novavax, a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, is proud to announce an exciting new partnership with the Los Angeles Rams aimed at "Protecting the Rams House" ...

Wall Street's three major indexes closed lower on Tuesday as investors booked some profits from a post-election rally and ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

Novavax stock fell sharply after the pharmaceutical company cut its forecast for annual revenue despite better-than-expected ...